- Home
- GPRK vs GOSS Comparison
GPRK vs GOSS Comparison
Compare GPRK & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- GOSS
- Stock Information
- Founded
- GPRK 2002
- GOSS 2015
- Country
- GPRK Colombia
- GOSS United States
- Employees
- GPRK N/A
- GOSS N/A
- Industry
- GPRK Oil & Gas Production
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- GOSS Health Care
- Exchange
- GPRK Nasdaq
- GOSS Nasdaq
- Market Cap
- GPRK 335.7M
- GOSS 347.8M
- IPO Year
- GPRK N/A
- GOSS 2019
- Fundamental
- Price
- GPRK $6.60
- GOSS $2.47
- Analyst Decision
- GPRK Buy
- GOSS Strong Buy
- Analyst Count
- GPRK 1
- GOSS 4
- Target Price
- GPRK $11.00
- GOSS $8.50
- AVG Volume (30 Days)
- GPRK 689.9K
- GOSS 3.1M
- Earning Date
- GPRK 08-05-2025
- GOSS 08-05-2025
- Dividend Yield
- GPRK 8.91%
- GOSS N/A
- EPS Growth
- GPRK N/A
- GOSS N/A
- EPS
- GPRK 0.81
- GOSS N/A
- Revenue
- GPRK $560,354,000.00
- GOSS $40,237,000.00
- Revenue This Year
- GPRK N/A
- GOSS N/A
- Revenue Next Year
- GPRK N/A
- GOSS $30.65
- P/E Ratio
- GPRK $8.19
- GOSS N/A
- Revenue Growth
- GPRK N/A
- GOSS N/A
- 52 Week Low
- GPRK $5.66
- GOSS $0.66
- 52 Week High
- GPRK $11.72
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- GPRK 50.84
- GOSS 68.08
- Support Level
- GPRK $6.28
- GOSS $2.38
- Resistance Level
- GPRK $6.67
- GOSS $2.65
- Average True Range (ATR)
- GPRK 0.20
- GOSS 0.15
- MACD
- GPRK 0.02
- GOSS 0.03
- Stochastic Oscillator
- GPRK 63.01
- GOSS 76.67
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.